Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.825 EUR | +0.18% | -2.59% | +3.86% |
03-15 | Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development | MT |
2023 | Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results | MT |
Sales 2021 | 1.93M 2.06M 2.82M | Sales 2022 | 1.9M 2.03M 2.77M | Capitalization | 5.1M 5.46M 7.46M |
---|---|---|---|---|---|
Net income 2021 | 1M 1.07M 1.46M | Net income 2022 | - 0 0 | EV / Sales 2021 | 3.77 x |
Net cash position 2021 | 486K 519K 710K | Net cash position 2022 | 421K 450K 615K | EV / Sales 2022 | 2.47 x |
P/E ratio 2021 |
4.78
x | P/E ratio 2022 |
14
x | Employees | 7 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 57.51% |
1 day | +0.18% | ||
1 week | -2.59% | ||
Current month | +3.10% | ||
1 month | +1.62% | ||
3 months | +2.73% | ||
6 months | +3.10% | ||
Current year | +3.86% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 94-12-31 | |
Patrice Coffe
DFI | Director of Finance/CFO | 55 | 08-06-30 |
Chief Tech/Sci/R&D Officer | - | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jean-Luc Rivière
BRD | Director/Board Member | - | 12-06-25 |
Chief Executive Officer | 50 | 94-12-31 | |
Patrice Coffe
DFI | Director of Finance/CFO | 55 | 08-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 2.825 | +0.18% | 47,644 |
24-04-25 | 2.82 | -5.69% | 46,585 |
24-04-24 | 2.99 | +0.50% | 27,701 |
24-04-23 | 2.975 | +0.85% | 23,157 |
24-04-22 | 2.95 | +1.72% | 8,884 |
Real-time Euronext Paris, April 26, 2024 at 11:35 am
More quotes1st Jan change | Capi. | |
---|---|---|
+3.86% | 9.99M | |
-12.23% | 194B | |
+0.74% | 166B | |
+2.19% | 153B | |
+4.34% | 99.85B | |
+7.04% | 77.56B | |
+19.09% | 73.55B | |
-7.30% | 71B | |
-20.54% | 52.81B | |
+0.53% | 47.86B |
- Stock Market
- Equities
- ALKLA Stock